Scilex Pharmaceuticals
Présence
Sorrento Therapeutics est une société cotée sous le symbole boursier SRNE (US).
Dirigeants
Voir l'organigramme avec ses 12 principaux dirigeants
Biographies les plus recherchées chez Scilex Pharmaceuticals
Changements de dirigeants chez Scilex Pharmaceuticals
- Elizabeth Czerepak, Executive Vice President, Chief Financial Officer and Chief Business Officer, a quitté l'entreprise (publié le 25 septembre 2023).
- Stephen Ma qui était Chief Accounting Officer, est promu Chief Financial Officer (publié le 25 septembre 2023).
- Tien Lee, Director, a quitté l'entreprise (publié le 6 septembre 2023).
Créer une alerte
pour suivre les mouvements de dirigeants chez Scilex Pharmaceuticals.
Pharmacie
Sorrento Therapeutics a 1 861 concurrents dont Pfizer (Etats—Unis), Sanofi (France) et Johnson & Johnson (Etats—Unis).
Actualités en fusion/acquisition en Pharmacie.
- MedMen has filed for bankruptcy protection (publié le 28 avril 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publié le 23 mars 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publié le 19 mars 2024).
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par Scilex Pharmaceuticals
- News & Events – Scilex Holding
- News & Events - Scilex Holding
- News - Scilex Holding
- Scilex Announces Addition of ZTlido® to Express Scripts National Formularies - Scilex Holding
- Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary Announces Expansion of Ztlido® Managed Care Coverage for Additional 33 Million Lives – SCILEX Pharmaceutical
- Scilex Holding Company, a Sorrento Company, Announces Complete Enrollment on Non-Opioid Injectable SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program For Sciatica Pain Management – SCILEX Pharmaceutical
- Scilex Holding, A Subsidiary of Sorrento, Has Received From FDA a sNDA Approval for Ztlido® Label Expansion – SCILEX Pharmaceutical
- Sorrento Therapeutics and Scilex Holding, a Majority Owned Subsidiary, Have Entered Into an Exclusive Licensing Term Sheet With Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndr
- Scilex Holding Company, a Subsidiary of Sorrento Therapeutics, Announces Continuous Sales Growth in ZTlido® and Expects to Complete Enrollment on its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial Program in 2020 – SCILEX Pharmaceutical
- Sorrento COVID-19 R&D October 13, 2020 Pipeline Call Details Released – SCILEX Pharmaceutical
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Scilex Pharmaceuticals
- Scilex Pharmaceuticals sur Wikipédia, Google News & Yahoo Finance en 1-click
- Scilex Pharmaceuticals sur LinkedIn, Twitter & YouTube en 1-click
Entrer en contact
Contacter par email ses dirigeants dont Jaisim Shah 
Appelez Scilex Pharmaceuticals au +1 610...
